Effects of serotonin-2A receptor binding and gender on personality traits and suicidal behavior in borderline personality disorder

Psychiatry Research - Neuroimaging

Volumn 222, Issue 3, 2014, Pages 140-148

  Soloff, Paul H ^a   Chiappetta, Laurel ^a   Mason, Neale Scott ^a   Becker, Carl ^a   Price, Julie C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aggression; Harm avoidance; Impulsivity; Novelty seeking; Positron emission tomography (PET); Suicidal behavior

Indexed keywords

ALTANSERIN; ALTANSERIN F 18; RADIOPHARMACEUTICAL AGENT; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGGRESSION; ALCOHOL ABUSE; AMYGDALOID NUCLEUS; ARTICLE; AVOIDANCE BEHAVIOR; BASAL GANGLION; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BORDERLINE STATE; CHILD ABUSE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG RECEPTOR BINDING; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; IMPULSIVENESS; MALE; OCCIPITAL CORTEX; PERSONALITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOCIAL BEHAVIOR; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUBSTANCE USE; SUICIDAL BEHAVIOR; TEMPERAMENT; TEMPORAL CORTEX;

AGGRESSION; HARM AVOIDANCE; IMPULSIVITY; NOVELTY SEEKING; POSITRON EMISSION TOMOGRAPHY (PET); SUICIDAL BEHAVIOR;

ADULT; AGGRESSION; BORDERLINE PERSONALITY DISORDER; CONTRAST MEDIA; DEPRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMPULSIVE BEHAVIOR; KETANSERIN; MALE; PERSONALITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; SEX FACTORS; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; TEMPERAMENT;

EID: 84901250945     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2014.03.008     Document Type: Article

References (78)

1. Arango V., Underwood M.D., Gubbi A.V., Mann J.J. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Research 1995, 688:121-133.
2. Audenaert K., Van Laere K., Dumont F., Slegers G., Mertens J., van Heeringen C., Dierckx R.A. Decreased frontal serotonin 5-HT 2a receptor binding index in deliberate self-harm patients. European Journal of Nuclear Medicine 2001, 28:175-182.
3. Bailer U.F., Price J.C., Meltzer C.C., Mathis C.A., Frank G.K., Weissfeld L., McConaha C.W., Henry S.E., Brooks-Achenbach S., Barbarich N.C., Kaye W.H. Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology 2004, 29:1143-1155.
4. Barratt E.S., Slaughter L. Defining, measuring, and predicting impulsive aggression: a heuristic model. Behavioral Sciences and the Law 1998, 16:285-302.
5. Beauchaine T.P., Klein D.N., Crowell S.E., Derbidge C., Gatzke-Kopp L. Multifinality in the development of personality disorders: a Biology×Sex×Environment interaction model of antisocial and borderline traits. Development and Psychopathology 2009, 21:735-770.
6. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961, 4:561-571.
7. Bhagwagar Z., Hinz R., Taylor M., Fancy S., Cowen P., Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. American Journal of Psychiatry 2006, 163:1580-1587.
8. Biegon A., Grinspoon A., Blumenfeld B., Bleich A., Apter A., Mester R. Increased serotonin 5-HT2 receptor binding on blood platelets of suicidal men. Psychopharmacology (Berlin) 1990, 100:165-167.
9. Biver F., Wikler D., Lotstra F., Damhaut P., Goldman S., Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. British Journal of Psychiatry 1997, 171:444-448.
10. Brambilla P., Soloff P.H., Sala M., Nicoletti M.A., Keshavan M.S., Soares J.C. Anatomical MRI study of borderline personality disorder patients. Psychiatry Research: Neuroimaging 2004, 131:125-133.
11. Brown G.L., Goodwin F.K. Cerebrospinal fluid correlates of suicide attempts and aggression. Annals of the New York Academy of Sciences 1986, 487:175-188.
12. Clarkin J.F., Hull J.W., Cantor J., Sanderson C. Borderline personality disorder and personality traits: a comparison of SCID-II BPD and NEO-PI. Psychological Assessment 1993, 5:472-476.
13. Cloninger C.R., Przybeck T.R., Svrakic D.M., Wetzel R.D. The Temperament and Character Inventory (TCI): A Guide to Its Development and Use 1994, Center for Psychobiology of Personality, Washington University, St. Louis, MO.
14. Coccaro E.F., Kavoussi R.J., Sheline Y.I., Berman M.E., Csernansky J.G. Impulsive aggression in personality disorder correlates with platelet 5-HT2A receptor binding. Neuropsychopharmacology 1997, 16:211-216.
15. Coccaro E.F., Kavoussi R.J., Sheline Y.I., Lish J.D., Csernansky J.G. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Archives of General Psychiatry 1996, 53:531-536.
16. Critchfield K.L., Levy K.N., Clarkin J.F. The relationship between impulsivity, aggression, and impulsive-aggression in borderline personality disorder: an empirical analysis of self-report measures. Journal of Personality Disorders 2004, 18:555-570.
17. Currier D., Mann J.J. Stress, genes and the biology of suicidal behavior. Psychiatric Clinics of North America 2008, 31:247-269.
18. da Cunha-Bang S., Stenbæk D.S., Holst K., Licht C.L., Jensen P.S., Frokjaer V.G., Mortensen E.L., Knudsen G.M. Trait aggression and trait impulsivity are not related to frontal cortex 5-HT2A receptor binding in healthy individuals. Psychiatry Research: Neuroimaging 2013, 212:125-131.
19. De La Fuente J.M., Goldman S., Stanus E., Vizuete C., Morlan I., Bobes J., Mendlewicz J. Brain glucose metabolism in borderline personality disorder. Journal of Psychiatric Research 1997, 31:531-541.
20. Driessen M., Herrmann J., Stahl K., Zwaan M., Meier S., Hill A., Osterheider M., Petersen D. Magnetic resonance imaging volumes of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. Archives of General Psychiatry 2000, 57:1115-1122.
21. Dwivedi Y., Pandey G.N. Quantitation of 5HT2A receptor mRNA in human postmortem brain using competitive RT-PCR. Neuroreport 1998, 9:3761-3765.
22. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (SCID-I/P, 4/2005 revision) 2005, Biometrics Research Department, New York State Psychiatric Institute, New York, NY.
23. Frokjaer V.G., Mortensen E.L., Nielsen F.A., Haugbol S., Pinborg L.H., Adams K.H., Svarer C., Hasselbalch S.G., Holm S., Paulson O.B., Knudsen G.M. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biological Psychiatry 2008, 63:569-576.
24. Frokjaer V., Vinberg M., Erritzoe D., Baare W., Holst K., Mortensen E., Arfan H., Madsen J., Jernigan T., Kessing L., Knudsen G. Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. Neuropsychopharmacology 2010, 35:1129-1137.
25. Gunderson J.G., Kolb J.E., Austin V. The diagnostic interview for borderline patients. American Journal of Psychiatry 1981, 138:896-903.
26. Hazlett E.A., New A.S., Newmark R., Haznedar M.M., Lo J.N., Speiser L.J., Chen A.D., Mitropoulou V., Minzenberg M., Siever L.J., Buchsbaum M.S. Reduced anterior and posterior cingulate gray matter in borderline personality disorder. Biological Psychiatry 2005, 58:614-623.
27. Johnson D.M., Shea M.T., Yen S., Battle C.L., Zlotnick C., Sanislow C.A., Grilo C.M., Skodol A.E., Bender D.S., McGlashan T.H., Gunderson J.G., Zanarini M.C. Gender differences in borderline personality disorder: findings from the Collaborative Longitudinal Personality Disorders Study. Comprehensive Psychiatry 2003, 44:284-292.
28. Kugaya A., Epperson C.N., Zoghbi S., van Dyck C.H., Hou Y., Fujita M., Staley J.K., Garg P.K., Seibyl J.P., Innis R.B. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. American Journal of Psychiatry 2003, 160:1522-1524.
29. Lemaire C., Cantineau R., Guillaume M., Plenevaux A., Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. Journal of Nuclear Medicine 1991, 32:2266-2272.
30. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. Journal of Cerebral Blood Flow and Metabolism 1990, 10:740-747.
31. Loranger A.W. International Personality Disorder Examination. DSM-IV and ICD-10 Interviews 1999, Psychological Assessment Resources, Inc., Lutz, FL.
32. Mann J.J. Neurobiology of suicidal behaviour. Nature Reviews: Neuroscience 2003, 4:819-828.
33. Mann J.J., Waternaux C., Haas G.L., Malone K.M. Toward a clinical model of suicidal behavior in psychiatric patients. American Journal of Psychiatry 1999, 156:181-189.
34. McBride P.A., Brown R.P., DeMeo M., Keilp J., Mieczkowski T., Mann J.J. The relationship of platelet 5-HT2 receptor indices to major depressive disorder, personality traits, and suicidal behavior. Biological Psychiatry 1994, 35:295-308.
35. McCloskey M.S., New A.S., Siever L.J., Goodman M., Koenigsberg H.W., Flory J.D., Coccaro E.F. Evaluation of behavioral impulsivity and aggression tasks as endophenotypes for borderline personality disorder. Journal of Psychiatric Research 2009, 43:1036-1048.
36. McGirr A., Paris J., Lesage A., Renaud J., Turecki G. Risk factors for suicide completion in borderline personality disorder: a case-control study of cluster B comorbidity and impulsive aggression. Journal of Clinical Psychiatry 2007, 68:721-729.
37. Meltzer C.C., Kinahan P.E., Greer P.J., Nichols T.E., Comtat C., Cantwell M.N., Lin M.P., Price J.C. Comparative evaluation of MR-based partial-volume correction schemes for PET. Journal of Nuclear Medicine 1999, 40:2053-2065.
38. Meltzer C.C., Smith G., Price J.C., Reynolds C.F., Mathis C.A., Greer P., Lopresti B., Mintun M.A., Pollock B.G., Ben-Eliezer D., Cantwell M.N., Kaye W., DeKosky S.T. Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Research 1998, 813:167-171.
39. Messa C., Colombo C., Moresco R.M., Gobbo C., Galli L., Lucignani G., Gilardi M.C., Rizzo G., Smeraldi E., Zanardi R., Artigas F., Fazio F. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berlin) 2003, 167:72-78.
40. Meyer J.H., McMain S., Kennedy S.H., Korman L., Brown G.M., DaSilva J.N., Wilson A.A., Blak T., Eynan-Harvey R., Goulding V.S., Houle S., Links P. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. American Journal of Psychiatry 2003, 160:90-99.
41. 18F]altanserin positron emission tomography. Biological Psychiatry 2004, 55:217-224.
42. Moses E.L., Drevets W.C., Smith G., Mathis C.A., Kalro B.N., Butters M.A., Leondires M.P., Greer P.J., Lopresti B., Loucks T.L., Berga S.L. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biological Psychiatry 2000, 48:854-860.
43. New A.S., Hazlett E.A., Buchsbaum M.S., Goodman M., Reynolds D., Mitropoulou V., Sprung L., Shaw R.B., Koenigsberg H., Platholi J., Silverman J., Siever L.J. Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Archives of General Psychiatry 2002, 59:621-629.
44. O[U+05F3]Leary K.M., Cowdry R.W.L.G.D., Leibenluft E.B.L.P., DeJong-Meyer R. Dysfunctional attitudes in Borderline Personality Disorder. Journal of Personality Disorders 1991, 5:233-242.
45. Oquendo M.A., Mann J.J. The biology of impulsivity and suicidality. Psychiatric Clinics of North America 2000, 23:11-25.
46. Pandey G.N., Pandey S.C., Dwivedi Y., Sharma R.P., Janicak P.G., Davis J.M. Platelet serotonin-2A receptors: a potential biological marker for suicidal behavior. American Journal of Psychiatry 1995, 152:850-855.
47. Paris J. Estimating the prevalence of personality disorders in the community. Journal of Personality Disorders 2010, 24:405-411.
48. Paris J., Zweig-Frank H. A 27-year follow-up of patients with borderline personality disorder. Comprehensive Psychiatry 2001, 42:482-487.
49. Peters J. The role of the medial orbitofrontal cortex in intertemporal choice: prospection or valuation?. Journal of Neuroscience 2011, 31:5889-5890.
50. Peters J., Buchel C. Episodic future thinking reduces reward delay discounting through an enhancement of prefrontal-mediotemporal interactions. Neuron 2010, 66:138-148.
51. Pollock L.R., Williams J.M. Effective problem solving in suicide attempters depends on specific autobiographical recall. Suicide and Life Threating Behavior 2001, 31:386-396.
52. Price J.C., Lopresti B.J., Mason N.S., Holt D.P., Huang Y., Mathis C.A. Analyses of [18 F] altanserin bolus injection PET data. I. Consideration of radiolabeled metabolites in baboons. Synapse 2001, 41:1-10.
53. Price J.C., Lopresti B.J., Meltzer C.C., Smith G.S., Mason N.S., Huang Y., Holt D.P., Gunn R.N., Mathis C.A. Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans. Synapse 2001, 41:11-21.
54. Prossin A.R., Love T.M., Koeppe R.A., Zubieta J-K, Silk K.R. Dysregulation of regional endogenous opioid function in borderline personality disorder. American Journal of Psychiatry 2010, 167:925-933.
55. Rosell D.R., Thompson J.L., Slifstein M., Xu X., Frankle W.G., New A., Goodman M., Weinstein S.R., Laruelle M., Abi-Dargham A., Siever L.J. Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biological Psychiatry 2010, 67:1154-1162.
56. Rylands A.J., Hinz R., Jones M., Holmes S.E., Feldmann M., Brown G., McMahon A.W., Talbot P.S. Pre- and postsynaptic serotonergic differences in males with extreme levels of impulsive aggression without callous unemotional traits: a positron emission tomography study using (11)C-DASB and (11)C-MDL100907. Biological Psychiatry 2012, 72:1004-1011.
57. Sala M., Caverzasi E., Lazzaretti M., Morandotti N., De Vidovich G., Marraffini E., Gambini F., Isola M., De Bona M., Rambaldelli G., d[U+05F3]Allio G., Barale F., Zappoli F., Brambilla P. Dorsolateral prefrontal cortex and hippocampus sustain impulsivity and aggressiveness in borderline personality disorder. Journal of Affective Disorders 2011, 131:417-421.
58. Schmahl C.G., Vermetten E., Elzinga B.M., Bremner J.D. Magnetic resonance imaging of hippocampal and amygdala volume in women with childhood abuse and borderline personality disorder. Psychiatry Research: Neuroimaging 2003, 122:193-198.
59. Siever L.J., Buchsbaum M.S., New A.S., Spiegel-Cohen J., Wei T., Hazlett E.A., Sevin E., Nunn M., Mitropoulou V. d,l-fenfluramine response in impulsive personality disorder assessed with [18F] fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 1999, 20:413-423.
60. Soloff P.H., Kelly T.M., Strotmeyer S.J., Malone K.M., Mann J.J. Impulsivity, gender, and response to fenfluramine challenge in borderline personality disorder. Psychiatry Research 2003, 119:11-24.
61. Soloff P.H., Lynch K.G., Kelly T.M. Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder. Journal of Personality disorders 2002, 16(3):201-214.
62. Soloff P.H., Meltzer C.C., Greer P.J., Constantine D., Kelly T.M. A fenfluramine-activated FDG-PET study of borderline personality disorder. Biological Psychiatry 2000, 47:540-547.
63. Soloff P.H., Nutche J., Goradia D., Diwadkar V. Structural brain abnormalities in borderline personality disorder: a voxel-based morphometry study. Psychiatry Research: Neuroimaging 2008, 164:223-236.
64. Soloff P.H., Price J.C., Mason N.S., Becker C., Meltzer C.C. Gender, personality, and serotonin-2A receptor binding in healthy subjects. Psychiatry Research: Neuroimaging 2010, 181:77-84.
65. Soloff P.H., Price J.C., Meltzer C.C., Fabio A., Frank G.K., Kaye W.H. 5HT2A receptor binding is increased in borderline personality disorder. Biological Psychiatry 2007, 62:580-587.
66. Stanley B., Siever L.J. The interpersonal dimension of borderline personality disorder: toward a neuropeptide model. American Journal of Psychiatry 2009, 167:24-39.
67. Staley J.K., Van Dyck C.H., Tan P.Z., Al Tikriti M., Ramsby Q., Klump H., Ng C., Garg P., Soufer R., Baldwin R.M., Innis R.B. Comparison of [(18)F]altanserin and [(18)F]deuteroaltanserin for PET imaging of serotonin(2A) receptors in baboon brain: pharmacological studies. Nuclear Medicine and Biology 2001, 28:271-279.
68. Tan P.Z., Baldwin R.M., Van Dyck C.H., Al-Tikriti M., Roth B., Khan N., Charney D.S., Innis R.B. Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. Nuclear Medicine and Biology 1999, 26:601-608.
69. Tebartz van Elst L., Hesslinger B., Thiel T., Geiger E., Haegele K., Lemieux L., Lieb K., Bohus M., Hennig J., Ebert D. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biological Psychiatry 2003, 54:163-171.
70. Trull T.J., Widiger T.A., Lynam D.R., Costa P.T. Borderline personality disorder from the perspective of general personality functioning. Journal of Abnormal Psychology 2003, 112:193-202.
71. van Heeringen C., Audenaert K., Van Laere K., Dumont F., Slegers G., Mertens J., Dierckx R.A. Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide. Journal of Affective Disorders 2003, 74:149-158.
72. Wall P.M., Messier C. The hippocampal formation-orbitomedial prefrontal cortex circuit in the attentional control of active memory. Behavioural Brain Research. 2001, 127:99-9117.
73. Wilberg T., Urnes O., Friis S., Pedersen G., Karterud S. Borderline and avoidant personality disorders and the five-factor model of personality: a comparison between DSM-IV diagnoses and NEO-PI-R. Journal of Personality Disorders 1999, 13:226-240.
74. Williams J.M., Broadbent K. Autobiographical memory in suicide attempters. Journal of Abnormal Psychology 1986, 95:144-149.
75. Yatham L.N., Liddle P.F., Shiah I.S., Scarrow G., Lam R.W., Adam M.J., Zis A.P., Ruth T.J. Brain serotonin2 receptors in major depression: a positron emission tomography study. Archives of General Psychiatry 2000, 57:850-858.
76. Zanarini M.C., Frankenburg F.R., Dubo E.D., Sickel A.E., Trikha A., Levin A., Reynolds V. Axis I comorbidity of borderline personality disorder. American Journal of Psychiatry 1998, 155:1733-1739.
77. Zanarini M.C., Gunderson J.G., Frankenburg F.R., Chauncey D.L. The Revised Diagnostic Interview for borderlines: discriminating BPD from other Axis II disorders. Journal of Personality Disorders 1989, 3:10-18.
78. Zlotnick C., Rothschild L., Zimmerman M. The role of gender in the clinical presentation of patients with borderline personality disorder. Journal of Personality Disorders 2002, 16:277-282.